**Additional File 2. GITR expression by CD4+, CD8+, and FoxP3+ cells**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Patient** | **Diagnosis** | **Cohort** | **Visit** | **CD4, % Positive\*** | **CD8, % Positive\*** | **FoxP3, % Positive\*** | **GITR, % Positive\*** |
| 1 | CRC | 180 mg | ScreeningC3, D43 | <11 | <1<1 | 31 | 00 |
| 2 | SCCHN | 180 mg | ScreeningC3, D43 | Missing<1 | Missing1 | 11 | 10 |
| 3 | TCC | 180 mg | ScreeningC3, D43 | 55 | 11 | 12 | 30 |
| 4 | CRC | 360 mg | ScreeningC3, D43 | 11 | 11 | 12 | 20 |
| 5 | SCCHN | 360 mg | ScreeningC3, D43 | 51 | 11 | 51 | 100 |
| 6 | NSCLC | 360 mg | ScreeningC3, D43 | MissingMissing | 1510 | 33 | 00 |
| 7 | SCCHN | 600 mg | ScreeningC3, D43 | 4025 | 3015 | 55 | 100 |
| 8 | SCCHN | 600 mg | ScreeningC3, D43 | 35 | 51 | 55 | 30 |
| 9 | TCC | 600 mg | ScreeningC3, D43 | 10 | 10 | <11 | 00 |
| 10 | CRC | 1200 mg | ScreeningC3, D43 | 3060 | 5040 | 58 | 10 |
| 11 | SCCHN | 1200 mg | ScreeningC3, D43 | 4060 | 5040 | 515 | 00 |
| 12 | CRC | 1200 mg | ScreeningC3, D43 | 4030 | 2050 | 200 | 101 |

CRC, colorectal cancer; NSCLC, non–small-cell lung cancer; SCCHN, squamous cell carcinoma of the head and neck; TCC, transitional carcinoma of the bladder.

aResult of 5% or greater is positive.